← Back to Patent Explorer
US4853386A Expired / Lapsed US ⏱️ 0.0 years remaining

N6 -disubstituted purine derivatives, and pharmaceutical compositions containing them, useful for treating allergic diseases, bronchospastic and bronchoconstrictory conditions

Assignee: Roche Diagnostics GmbH
•
Filing: 1986-08-15
•
Granted: 1989-08-01
•
Expires: 2006-08-15
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention provides N6-disubstituted purine derivatives of the general formula: <IMAGE> (I) wherein R1 and R4 are the same or different and each represents a hydrogen or halogen atom or an -NR6R7 group, R2 and R3 are the same or different and each represents a C1-C6 alkyl radical, a C2-C6 alkenyl radical, a C3-C7 cycloalkyl radical, a phenalkyl radical containing up to 4 carbon atoms in the alkyl moiety, which can be straight-chained or branched, the phenyl moiety of which can be substituted one or more times by halogen, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylthio or trifluoromethyl; a furylmethyl or furylethyl radical, a thiophenemethyl or thiopheneethyl radical, a pyridylmethyl or pyridylethyl radical optionally substituted by a C1-C4 alkyl radical, an indanyl radical or a tetrahydronaphthyl radical, R5 is a hydrogen atom, a tetrahydrofuranyl or tetrahydropyranyl radical or a C1-C10 radical which is optionally substituted one or more times by hydroxyl, C1-C6 alkanoyloxy, C1-C6 alkoxycarbonyl, C2-C6 carboxyalkanoyloxy, C2-C6 hydroxyalkoxy, C3-c6 dihydroxyalkoxy, carboxyl, cyano or 1H-tetrazol-5-yl radical, R6 and R7 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl radical or together represent a C2-C5 alkylene radical optionally interrupted by oxygen, sulphur or an NR8 group and R8 is a hydrogen atom or a C1-C6 alkyl radical; as well as the pharmacologically acceptable salts thereof.

Inventors

  • 👤 Walter-Gunar Friebe
  • 👤 Otto-Henning Wilhelms

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 15:41
CPC Classifications
C; C07; C07D; C07D473/00; A; A61; A61P; A61P11/00; A61P11/08; A61P37/00; A61P37/08; C07D473/02; C07D473/16; C07D473/26; C07D473/32; C07D473/34

Claims Analysis

Total Claims: 27
Claim 1
Independent Claim 262 words
A compound of the formula: ##STR4## wherein R 1 and R 4 are individually a hydrogen atom, a halogen atom or NR 6 R 7 , R 6 and R 7 are individually hydrogen, C 1 -C 6 alkyl radical and R 2 and R 3 are individually alkyl radicals of from 1 to 6 carbon atoms, alkenyl radicals of from 2 to 6carbon atoms, cycloalkyl radicals of from 3 to 7 carbon atoms, phenylalkyl radicals containing alkyl groups of from 1 to 4 carbon atoms and the phenyl moiety of which is unsubstituted or substituted by halogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio or trifluoromethyl, furylmethyl, furylethyl, thiophenemethyl, thiopheneethyl, pyridylmethyl, pyridylethyl, the pyridyl moieties of which are unsubstituted or substituted by C 1 -C 4 alkyl radicals, indanyl or tetrahydronapthyl radicals and R 5 is hydrogen, a tetrahydrofuranyl radical, a tetrahydropyranyl radical, or an alkyl radical of from 1 to 10 carbon atoms which is unsubstituted or substituted by hydroxyl, C 1 -C 6 alkanoyloxy, C 1 -C 6 alkoxycarbonyl, C 2 -C 6 carboxyalkanoyloxy, C 2 -C 6 hydroxyalkoxy, C 3 -C 6 dihydroxyalkoxy, carboxyl, cyano or 1H-tetrazol-5-yl radical, or pharmaceutically acceptable salts thereof provided that (i) R 2 and R 3 are not simultaneously alkyl radicals, or (ii) when R 5 is hydrogen, then R 2 and R 3 are not simultaneously alkenyl, unsubstituted benzyl or furylmethyl, or (iii) when R 3 is methyl and R 5 is hydrogen, then R 2 is not alkenyl, unsubstituted benzyl or furylmethyl.
Claim 2
Dependent Claim 262 words
A compound of the formula: ##STR4## wherein R 1 and R 4 are individually a hydrogen atom, a halogen atom or NR 6 R 7 , R 6 and R 7 are individually hydrogen, C 1 -C 6 alkyl radical and R 2 and R 3 are individually alkyl radicals of from 1 to 6 carbon atoms, alkenyl radicals of from 2 to 6carbon atoms, cycloalkyl radicals of from 3 to 7 carbon atoms, phenylalkyl radicals containing alkyl groups of from 1 to 4 carbon atoms and the phenyl moiety of which is unsubstituted or substituted by halogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio or trifluoromethyl, furylmethyl, furylethyl, thiophenemethyl, thiopheneethyl, pyridylmethyl, pyridylethyl, the pyridyl moieties of which are unsubstituted or substituted by C 1 -C 4 alkyl radicals, indanyl or tetrahydronapthyl radicals and R 5 is hydrogen, a tetrahydrofuranyl radical, a tetrahydropyranyl radical, or an alkyl radical of from 1 to 10 carbon atoms which is unsubstituted or substituted by hydroxyl, C 1 -C 6 alkanoyloxy, C 1 -C 6 alkoxycarbonyl, C 2 -C 6 carboxyalkanoyloxy, C 2 -C 6 hydroxyalkoxy, C 3 -C 6 dihydroxyalkoxy, carboxyl, cyano or 1H-tetrazol-5-yl radical, or pharmaceutically acceptable salts thereof provided that (i) R 2 and R 3 are not simultaneously alkyl radicals, or (ii) when R 5 is hydrogen, then R 2 and R 3 are not simultaneously alkenyl, unsubstituted benzyl or furylmethyl, or (iii) when R 3 is methyl and R 5 is hydrogen, then R 2 is not alkenyl, unsubstituted benzyl or furylmethyl.
Claim 3
Dependent Claim 14 words
The compound of claim 1, wherein R 1 and R 4 are the same.
Claim 4
Dependent Claim 15 words
The compound of claim 1, wherein R 1 and R 4 are hydrogen or halogen.
Claim 5
Dependent Claim 17 words
The compound of claim 1, wherein R 1 or R 4 are N--R 6 R 7 .
Claim 6
Dependent Claim 29 words
The compound of claim 1, wherein R 6 and R 7 are selected from the group consisting of hydrogen and alkyl radicals of from 1 to 6 carbon atoms.
Claim 7
Dependent Claim 11 words
The compound of claim 5, wherein said alkyl radical is methyl.
Claim 8
Dependent Claim 52 words
The compound of claim 1, wherein R 2 and R 3 are individually 2-propyl, 2-methylpropyl, 3-pentyl, allyl, cyclopentyl, cyclohexyl or indanyl radical or a benzyl radical optionally substituted one or more times by chlorine, fluorine, methyl, triflouromethyl or methoxy; a furylmethyl, thiophenemethyl, thiopheneethyl group or a pyridinemethyl radical optionally substituted by methyl.
Claim 9
Dependent Claim 24 words
The compound of claim 1, wherein R 5 is hydrogen, tetrahydrofuran-2-yl, tetrahydropyran-2-yl, 2-hydroxypropyl, 2,3-dihydroxypropyl, 2-acetoxypropyl, 2-succinoyloxypropyl, (2-hydroxyethoxy)-methyl, 1-(1,3-dihydroxy-2-propoxy)-2-hydroxyethyl, 8-methoxycarbonyloctyl, 8-carboxyoctyl, 4-cyanobutyl or 4-(1H-tetrazol-5-yl)-butyl radical.
Claim 10
Dependent Claim 12 words
The compound of claim 1, designated 6-(N-benzyl-N-cyclopentylamino)-9-tetrahydrofuran-2-yl-purine or pharmaceutically acceptable salts thereof.
Claim 11
Dependent Claim 12 words
The compound of claim 1, designated 6-[N-cyclopentyl-N-(2,5-dimethylbenzyl)-amino]-9-tetrahydropyran-2-yl-purine or pharmaceutically acceptable salts thereof.
Claim 12
Dependent Claim 12 words
The compound of claim 1, designated 6-[N-indan-1-yl)-N-(2-methylpropyl)-amino]-9-tetrahydropyran-2-yl-purine or pharmaceutically acceptable salts thereof.
Claim 13
Dependent Claim 13 words
The compound of claim 1, designated 6-[N-cyclopentyl-N-(thiophen-2-yl methyl)-amino]-purine or pharmaceutically acceptable salts thereof.
Claim 14
Dependent Claim 12 words
The compound of claim 1, designated 6-[N-cyclopentyl-N-(4-methoxybenzyl)-amino]-purine or pharmaceutically acceptable salts thereof.
Claim 15
Dependent Claim 12 words
The compound of claim 1, designated 6-(N-allyl-N-cyclohexylamino)-2-methylaminopurine or pharmaceutically acceptable salts thereof.
Claim 16
Dependent Claim 12 words
The compound of claim 1, designated 6-(N-allyl-N-cyclohexylamino)-purine or pharmaceutically acceptable salts thereof.
Claim 17
Dependent Claim 12 words
The compound of claim 1, designated 6-[N-cyclopentyl-N-(6-methylpyridin-2-ylmethyl)-amino]-purine or pharmaceutically acceptable salts thereof.
Claim 18
Dependent Claim 12 words
The compound of claim 1, designated 6-[N-cyclopentyl-N-(2,5-dimethylbenzyl)-amino]-9-tetrahydrofuran-2-yl-purine or pharmaceutically acceptable salts thereof.
Claim 19
Dependent Claim 13 words
The compound of claim 1, designated 6-[N-cyclopentyl-N-(2,5-dimethyl benzyl)-amino]-9-(2,3-dihydroxypropyl)-purine or pharmaceutically acceptable salts thereof.
Claim 20
Dependent Claim 12 words
The compound of claim 1, designated 6-[N-(-chloro-2-methoxybenzyl)-N-cyclopentylamino]-9-(2,3-dihydroxypropyl)-purine or pharmaceutically acceptable salts thereof.
Claim 21
Dependent Claim 27 words
The composition useful in treating allergic diseases, bronchospastic and bronchoconstrictory conditions, comprising a therapeutically effective amount of the compound of claim 1, in a pharmaceutically acceptable carrier.
Claim 22
Dependent Claim 35 words
The composition of claim 20, wherein said compound is selected from the group consisting of 6-[N-cyclopentyl-N-(2,5-dimethylbenzyl)-amino]-9-tetrahydropyran-2-yl-purine, 6-[N-(indan-1-yl)-N-(2-methylpropyl)-amino]-9-tetrahydropyran-2-yl-purine, 6-[N-benzyl-N-cyclopentylamino)-9-tetrahydrofuran-2-yl-purine, 6-[N-cyclopentyl-N-(thiophen-2-yl methyl)-amino]-purine, 6-cyclopentyl-N-(4-methoxybenzyl)-amino]-purine, 6-N-allyl-N-cyclohexylamino)-2-methylaminopurine, 6-(N-allyl-N-cycloyhexylamino)-purine, 6-[N-cyclopentyl-N-(6-methyl pyridin-2-ylmethyl)-amino]-purine, 6-[N-cyclopentyl-N-(2,5-dimethylbenzyl)-amino]-9-tetrahydrofuran-2-yl-purine, 6-[N-cyclopentyl-N-(2,5-dimethyl benzyl)-amino]-9-(2,3-dihydroxypropyl)-purine, 6-[N-(5-chloro-2-methoxybenzyl)-N-cyclopentylamino]-9-(2,3-dihydroxypropyl)-purine pharmaceutically acceptable salts of said compounds.
Claim 23
Dependent Claim 30 words
A method of treating allergic diseases, bronchospastic and bronchoconstrictory conditions, comprising administering to a subject a therapeutically effective amount of the compound of claim 1 in a pharmaceutically acceptable carrier.
Claim 24
Dependent Claim 31 words
A method of claim 22, wherein said compound is administered in an amount ranging from about 0.1 to about 50 mg/kg of body weight of said subject per day of treatment.
Claim 25
Dependent Claim 32 words
A method as in claim 22, wherein said compound is a administered in an amount ranging from about 0.5 to 40 mg/kg of body weight of said subject per day of treatment.
Claim 26
Dependent Claim 32 words
A method as in claim 22, wherein said compound is administered in an amount ranging from about 1.0 to about 10 mg/kg of body weight of said subject per day of treatment.
Claim 27
Dependent Claim 36 words
A method as claim 22, wherein said compound is selected from the group consisting of 6-[N-cyclopentyl-N-(2,5-dimethylbenzyl)-amino]-9-tetrahydropyran-2-yl-purine, 6-[N-(indan-1-yl)-N-(methylpropyl)-amino]-9-tetrahydropyran-2-yl-purine, 6-[N-benzyl-N-cyclopentyl-amino)-9-tetrahydrofuran-2-yl-purine, 6-[N-cyclopentyl-N-(thiophen-2-yl methyl)-amino]-purine, 6-cyclopentyl-N-(4-methoxybenzyl)-amino]-purine, 6-N-allyl-N-cyclohexylamino)-2-methylaminopurine, 6-(N-allyl-N-cycloyhexylamino)-purine, 6-[N-cyclopentyl-N-(6-methyl-pyridin-2-ylmethyl)-amino]-purine, 6-[N-cyclopentyl-N-(2,5-dimethylbenzyl)-amino]-9-tetrahydrofuran-2-yl-purine, 6-[N-cyclopentyl-N-(2,5-dimethyl benzyl)-amino]-9-(2,3-dihydroxypropyl)-purine, 6-[N-(5-chloro-2-methoxybenzyl)-N-cyclopentylamino]-9-(2,3-dihydroxypropyl)-purine, or a pharmaceutically acceptable salts of said compounds.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1992-07-31 1993-01-30 1993-08-01 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1996-07-31 1997-01-30 1997-08-01 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2000-07-31 2001-01-30 2001-08-01 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag